PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Nefopam→

Nefopam PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
13669-70-0
Molecular formula
C17H19NO
Molecular weight
253.34 g/mol
Drug class
Centrally acting non-opioid analgesicbenzoxazocine derivative
Mechanism of action
The precise mechanism is not fully established. Nefopam inhibits reuptake of serotonin, noradrenaline and dopamine and also modulates neuronal sodium and calcium channels, reducing central nociceptive transmission. It does not act through opioid receptors and does not produce the typical opioid respiratory-depressant mechanism.
Indications / reported uses
  • Relief of acute and chronic pain, including postoperative, dental, musculoskeletal, traumatic and cancer pain, according to the authorised product label.

Sources: https://www.medicines.org.uk/emc/product/15926/smpc · https://www.medicines.org.uk/emc/product/11685/smpc · https://sps.nhs.uk/articles/use-of-nefopam-for-chronic-pain/ · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Nefopam PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Nefopam Permitted Daily Exposure (PDE) report (the Nefopam PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Nefopam Occupational Exposure Limit (OEL) report (the Nefopam OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.